Oncolytics Biotech Inc. (ONCY)

[Timetravelerdos]

Oncolytics Biotech® Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 12, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the acceptance of an abstract highlighting new biomarker data from the randomized study NCI 8601: Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer. The data will be part of a poster presentation at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO, January 23 - 25, 2020, in San Francisco.

The abstract, CEACAM6 is a candidate biomarker for REOLYSIN® (pelareorep) sensitivity in pancreatic adenocarcinoma (PDAC), was co-authored by Dr. Anne Noonan, Department of Medical Oncology, Ohio State University Wexner Medical Center, Richard Solove Research Institute and James Cancer Hospital, and Dr. Tanios Bekaii-Saab Senior Associate Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona.

https://ir.oncolyticsbiotech.com/press-releases/detail/489/oncolytics-biotechr-announces-abstract-outlining